trending Market Intelligence /marketintelligence/en/news-insights/trending/cWa-r_IGqKdCjNMmuC7Z8Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Ionis earns $10M milestone payment from Biogen for Alzheimer's study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ionis earns $10M milestone payment from Biogen for Alzheimer's study

Ionis Pharmaceuticals Inc. said it earned a $10 million milestone payment from Biogen Inc. upon initiation of the phase 1/2a trial of IONIS-MAPT in patients with mild Alzheimer's disease.

Ionis and Biogen are jointly developing novel therapies, such as the antisense drug Spinraza, to treat neurological disorders.

Under their partnership, the companies are developing IONIS-SOD1 for amyotrophic lateral sclerosis, as well as IONIS-BIIB5, IONIS-BIIB6 and IONIS-BIIB7 for undisclosed neurodegenerative diseases.